Polaris Partners

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

BeMe Health is a mobile application focused on promoting the mental health and emotional wellbeing of teenagers. Founded by Casey Neistat and Matt Hackett, it offers curated content, learning opportunities, and live coaching sessions led by professionals. The platform encourages peer interaction and engagement, blending social features with clinical care to empower users in managing their mental health effectively.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

Lore Health is a startup that combines artificial intelligence (AI) technology with social media to build a welcoming, encouraging, and judgment-free community where individuals may meet others who share their interests.

Livara Health is a provider of non-operative, personalized treatment for musculoskeletal conditions, focusing specifically on back and neck problems. The company has developed an orthopedic care management platform that offers a data-driven, non-invasive back pain program. This program assesses patients' needs and customizes a comprehensive six-week treatment plan aimed at delivering relief. Patients receive physical therapy coaching, which can be accessed both online and onsite, to support their progress throughout the program. Livara Health's approach allows individuals to manage their musculoskeletal issues effectively without the need for surgical intervention.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on cancer therapeutics. It operates a laboratory dedicated to studying cancer-driving pathways and developing treatments that target and over-activate specific cancer-linked cell signaling, ultimately leading to the death of tumor cells.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Over millions and millions of years, a collection of reward systems

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, founded in 2019. The company specializes in developing a platform that enhances collaboration among healthcare stakeholders, including patients, providers, and payers. Cohere Health focuses on improving the efficiency and effectiveness of healthcare delivery by simplifying complex processes through technology. Its primary offering is an intelligent prior authorization solution that is configurable to meet the specific needs of different health plans. This solution can be implemented as a fully outsourced utilization management service, utilizing artificial intelligence, machine learning, and real-time analytics to automate the prior authorization process. By doing so, Cohere Health aims to facilitate seamless communication and guide quality care throughout the patient journey, ultimately improving patient outcomes.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

UpDoc is a technology-enabled services firm that offers the world's first unique conversational AI platform for autonomous prescription management.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Sovato Health specializes in remote surgical access, offering a platform that connects skilled surgeons with patients in underserved areas. This platform integrates people, systems, tools, data, and business models to ensure safe, scalable, and sustainable remote surgical procedures.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

65LAB is a biotechnology company that specializes in accelerating the development of innovative therapies. It operates an accelerator program designed to commercialize promising therapeutic projects. The company identifies potential therapies from applicants, provides funding and mentoring, and helps these projects achieve preclinical proof-of-concept.

Best Doctors is a healthcare services company that offers an innovative employee benefit program. This program provides access to global medical expertise for employees facing significant health decisions, ensuring accurate diagnoses and treatments. The company facilitates consultations between patients and top-tier specialists worldwide, enhancing the quality of care while potentially reducing overall healthcare costs.

Contact Networks offers Enterprise Relationship Management (ERM) software solutions designed to help professional services firms maximize the value of their relationship networks for business development. Their flagship product, ContactNet, is an automated search application that quickly identifies employees with strong relationships to a client or prospect. Based in Boston, MA, Contact Networks was acquired by Thomson Reuters in 2007.

The Company offers infrastructure for comprehensive live collaboration including voice over the internet.

CyberSafe offers a range of Kerberos-based security solutions for SAP business applications. The company’s product portfolio includes ActiveTRUST Security Software, TrustBroker Security Suite, Defensor, and Centrax, all designed to enable secure electronic transactions and reduce administration costs. CyberSafe was founded in 1991 and is headquartered in Issaquah, Washington.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on mitigating healthcare cyber incidents related to patient data theft, addressing a critical need for chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patient health information (PHI). By implementing a proactive risk management approach, the software aims to improve patient care, clinician satisfaction, regulatory compliance, and foster innovation within healthcare organizations.

Simon Data, Inc. is a Brooklyn-based company that specializes in developing a performance marketing platform, which includes a customer data platform designed to empower marketers in creating sophisticated client segmentations. Founded in 2013, Simon Data's platform enables organizations to enhance their personalization capabilities without the necessity for extensive customized data infrastructure. This innovative approach allows brands to deliver exceptional customer experiences across various channels by providing solutions for data ingestion, a personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis. Originally known as Radico, Inc., the company rebranded to Simon Data, Inc. in November 2013.

Vita Health operates an online mental health care platform focused on providing high-quality treatment for adolescents and transitional age youth. The platform enables patients to receive quick and accessible care from licensed therapists through telehealth services. It addresses various mental health challenges, including anxiety, depression, and suicidal ideation, ensuring that young individuals can conveniently access the support they need from the comfort of their homes.

Tisento Therapeutics, based in Massachusetts, specializes in developing innovative medicines to address diseases with substantial unmet medical needs. Its primary focus is on Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke (MELAS), a severe mitochondrial disorder. The company's therapies aim to treat mitochondrial diseases, both in the central nervous system and peripherally, by targeting key aspects of the disease's pathophysiology, including neuronal and mitochondrial function, cerebrovascular hemodynamics, and inflammatory processes. This approach enables patients to receive treatment promptly.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Crossbow Therapeutics is a biotechnology company focused on developing innovative cancer treatments. The company engineers antibodies to mimic T-cells, which are essential components of the immune system, aiming to enhance the quality of life for cancer patients. Their next-generation immunotherapies are designed to target previously unreachable cancer cell proteins with high precision, offering an efficient and selective approach to cancer treatment. By unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies, Crossbow Therapeutics seeks to dramatically expand the capabilities of antibody therapy across various cancer types, ultimately improving patient outcomes.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

Candesant Biomedical, Incorporated is a medical device company focused on developing innovative solutions for excessive sweating and hyperhidrosis. Founded in 2015 and based in San Francisco, California, the company offers a proprietary device known as CDX-101, which utilizes water-activated technology to target and inactivate active sweat glands without causing discomfort to patients. The technology operates on the principle that alkali metals generate energy upon contact with water, allowing for precise energy delivery to the specific areas where sweat glands are most active. This approach not only aims to reduce excessive sweating but also helps inhibit bacterial growth associated with hyperhidrosis, providing a significant improvement in the quality of life for affected individuals.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at enhancing cancer treatment. The company focuses on understanding how tumors manipulate the immune system and seeks to address these challenges by targeting specific molecular characteristics of patient populations. Larkspur's innovative approach is designed to foster a robust and sustained immune response, particularly in colorectal cancer, while also exploring applications for other cancers. By aligning its therapies with the unique molecular profiles of tumors, Larkspur aims to improve treatment outcomes for patients facing the complexities of cancer.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By investigating the unique characteristics of the bat genome, the company aims to identify and develop therapeutics for various diseases. Leveraging insights gained from bat biology, Paratus Sciences seeks to enable patients to combat and potentially cure the diseases they face. Through its innovative approach, the company aspires to contribute significantly to advancements in medical treatments and public health.

Faro Health is a developer of a cloud-based medical platform that aims to standardize, automate, and streamline the challenges associated with clinical trials. The company's innovative platform utilizes an integrated clinical development environment, which simplifies the design and authoring processes of complex clinical studies. By leveraging advanced digital protocols, Faro Health provides clinical researchers with in-context, intuitive insights throughout the authoring process. This approach allows researchers to optimize their study designs by reducing the administrative burden of clinical protocols, enabling them to concentrate on the critical decisions that enhance clinical value.

August Bioservices, LLC is a contract development and manufacturing organization (CDMO) based in Nashville, Tennessee, with an additional office in Celina, Tennessee. Established in 2017, the company specializes in offering a wide range of services for drug discovery, pharmaceutical development, and clinical manufacturing. Its research services encompass target validation, functional characterization, assay development, drug discovery, protein engineering, and both in vitro and in vivo testing. In the pharmaceutical development arena, August Bioservices provides formulation, process design, optimization, scale-up, and analytical method development. The company's clinical manufacturing capabilities include clinical trial supply, cGMP non-sterile and bulk manufacturing, aseptic fill and finish, and quality control. Additionally, it offers various testing services, such as pregnancy testing and viral disease testing, to clients in the pharmaceutical and biotechnology sectors. August Bioservices was previously known as PMI BioPharma Solutions until its name change in July 2020.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

CoV Biotechnology is an early-stage biotechnology company dedicated to addressing the challenges posed by the evolving and mutating nature of coronaviruses. The company develops booster vaccines and therapeutics specifically designed to combat variants of the SARS-2 beta coronavirus. By focusing on creating vaccines that offer broad-spectrum protection against both current and future variants, as well as potential zoonotic crossovers from animals to humans, CoV Biotechnology aims to provide effective solutions to enhance immunity and reduce the impact of future coronavirus pandemics.

Capstan Therapeutics is a biotechnology company focused on advancing precision in vivo cell engineering to create therapeutics for various disease categories that have unmet or underserved clinical needs. The company specializes in expanding the therapeutic potential of RNA-based therapies through proprietary targeted delivery systems. Their platform utilizes targeted lipid nanoparticles to enhance off-the-shelf immunotherapies, providing tight control over dosage and activity of engineered cells. This approach aims to develop transformative products for conditions such as oncology, fibrosis, and inflammation-related diseases.

Amplifire is a company that specializes in developing an online learning platform designed to enhance individual performance and knowledge retention. The platform employs advanced learning algorithms and knowledge analytics to deliver measurable results in various sectors, including education, healthcare, and corporate environments. By focusing on diagnostic capabilities, Amplifire aims to empower users to learn effectively and apply their skills in real-world scenarios, ultimately enabling organizations to thrive in competitive markets. The company's innovative approach to learning supports individuals in reaching their highest potential while improving overall performance in their respective fields.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Foresight Mental Health is a technology-driven provider of psychiatry and therapy services, operating a network of clinics dedicated to mental health and wellness. The company employs a diverse team that includes psychiatrists, therapists, and psychiatric nurse practitioners who deliver care directly to patients. Foresight enhances its treatment offerings through innovative technology developed in collaboration with software and biomedical engineers, aimed at transforming the mental healthcare experience. By utilizing comprehensive patient profiles and a database of scientific research, the company conducts detailed analyses that include genetic profiles and assessments of brain-chemical balance. This holistic approach enables Foresight to offer tailored treatments, ultimately helping patients achieve improved mental health and overall well-being.

Scholar Rock, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of biologic therapies that selectively target dysregulated growth factors within disease microenvironments. The company's innovative approach focuses on modulating supracellular activation to address serious diseases, including fibrosis, musculoskeletal disorders, immuno-oncology, and autoimmune diseases. Scholar Rock's lead product candidate, SRK-015, is a first-in-class inhibitor designed to target the activation of the growth factor myostatin in skeletal muscle, specifically for the treatment of spinal muscular atrophy. The company is advancing this candidate through clinical development while also leveraging its proprietary platform to create a pipeline of additional product candidates aimed at transforming treatment for various serious conditions, including other neuromuscular disorders, cancer, and anemia.

Tessa Therapeutics is a biotechnology company specializing in T cell therapy aimed at treating cancer, particularly solid tumors and lymphoma. The company focuses on developing both autologous and allogeneic cell therapies, including virus-specific T-cells and CAR T cells. Tessa Therapeutics aims to harness the body's anti-viral immune response to target and eliminate cancer cells, thereby transforming cancer treatment and enhancing the quality of life for patients. Through its innovative platform, Tessa Therapeutics is committed to advancing therapeutic options for healthcare providers and improving patient outcomes in the fight against cancer.

Podimetrics, Inc. is a healthcare technology company specializing in the prevention of diabetic foot ulcers, a significant complication of diabetes. Founded in 2011 and based in Somerville, Massachusetts, Podimetrics has developed the SmartMat, a wireless in-home monitoring system that enables patients to scan their foot temperature for just 20 seconds each day. This data is automatically transmitted to a dedicated care management team, which monitors for any concerning findings. By integrating advanced technology with effective clinical support, Podimetrics enhances patient engagement and helps clinicians achieve better health outcomes, ultimately saving limbs, lives, and healthcare costs. The company was founded by a physician and engineers from prestigious institutions, reflecting its commitment to innovation in diabetes care management.

TRexBio is a biotechnology company that leverages cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop therapeutics for cancer and inflammatory diseases. Its 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, identifying and characterizing novel targets for therapeutic intervention. The platform supports the development of a portfolio of therapies that modulate the immune system to restore tissue immune homeostasis.

Satellite Bio is a company dedicated to advancing cell therapy and regenerative medicine through innovative approaches in synthetic biology and tissue engineering. It develops proprietary, off-the-shelf implantable satellite organs, which are designed as living therapeutic solutions aimed at addressing complex diseases. By focusing on creating these advanced cell therapies, Satellite Bio seeks to transform the lives of patients suffering from serious health conditions, offering new hope for effective treatment options.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Seismic Therapeutic is a biotechnology company focused on advancing immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its proprietary IMPACT™ platform, Seismic Therapeutic addresses critical challenges in the development of biologics by combining machine learning with structural biology, protein engineering, and translational immunology. This innovative approach aims to create optimized therapies for patients more efficiently. The company is developing a pipeline of biologics specifically targeting adaptive immune system dysregulation to treat various autoimmune diseases.

Dewpoint Therapeutics, Inc. is a Boston-based biotech company focused on the research and development of biomolecular condensates, aiming to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunological conditions, cardiovascular issues, women's health, and viral infections. Founded in 2018, the company utilizes a proprietary platform that combines experimental techniques with machine-learning-based image analysis to visualize and study biomolecular condensates. This technology includes a collection of genetically engineered cell lines designed to track condensates and mitigate harmful protein sequestration. By leveraging its advanced capabilities, Dewpoint Therapeutics seeks to address unmet medical needs and enhance drug discovery across multiple therapeutic areas, collaborating with leading academic and pharmaceutical partners to further its mission.

76Bio is a biotechnology company founded in 2020 and based in New York, focused on developing innovative therapies for patients with life-threatening diseases. The company specializes in creating targeted protein degraders, a novel approach that aims to degrade or break down unneeded proteins in the body. By leveraging advanced biotechnology, 76Bio seeks to deliver transformational therapies that address critical medical needs and improve patient outcomes through next-generation treatments.

Ankyra is a biotech company focused on developing anchored immunotherapy to enhance cancer treatment. The company's innovative approach addresses the challenges associated with traditional cytokine therapeutics, which often face limitations due to widespread immune activation and toxicity when administered systemically. Ankyra utilizes its Anchored Immunotherapy Platform to create ANK-101, a stable complex that combines a modified IL-12 cytokine with an FDA-approved adjuvant, aluminum hydroxide, which helps to retain the cytokine's potent activity at the tumor site. This localized delivery results in targeted inflammation that activates an anti-tumor immune response while minimizing adverse effects. Ankyra aims to optimize the efficacy and safety of its therapies, ultimately improving treatment outcomes for cancer patients.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Sonrai Security Inc. is a provider of an enterprise identity and data governance platform designed for cloud environments including AWS, Azure, Google Cloud, and Kubernetes. Founded in 2017 and based in New York, with additional offices in Canada, the company focuses on enhancing security for organizations by identifying and monitoring relationships between identities and data within public clouds. Its flagship product, the Sonrai Dig platform, features a Governance Automation Engine that streamlines workflows, remediation, and prevention efforts for security and DevOps teams, thereby ensuring comprehensive security and compliance. Sonrai Security caters to a diverse range of sectors, including education, financial services, healthcare, and telecommunications, addressing the needs of security, audit, governance, risk, and compliance teams across various industries.

Neumora Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for brain diseases by combining data science with neuroscience. Founded to address the global brain disease crisis, Neumora takes an innovative approach to treatment development. The company has established a robust therapeutic pipeline that includes seven clinical and preclinical neuroscience programs targeting novel mechanisms of action for various underserved neuropsychiatric and neurodegenerative disorders. Neumora plans to advance its pipeline further by initiating multiple clinical trials across its programs in the upcoming 12 to 18 months.

Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

ByHeart, Inc. is a New York-based company specializing in the development of infant and baby nutritional food products. Founded in 2016, ByHeart focuses on creating formulas and foods that support various aspects of babies' health, including immune, microbiome, cognitive, and digestive health. The company emphasizes the use of hand-picked ingredients and small-batch blending to ensure high-quality, nutritious options for young children. ByHeart aims to translate advanced nutrition science and breastmilk research into innovative products that provide parents with peace of mind while proactively fostering a strong foundation for their babies’ future health. The company operates facilities in Pennsylvania, reinforcing its commitment to quality and safety in infant nutrition.

FloQast, Inc. is a financial close management software company that specializes in streamlining the month-end close process for accounting teams. Its platform provides tools for task management, documentation, reconciliation, and reporting, enabling organizations to enhance collaboration, visibility, and efficiency. Key offerings include FloQast Close, which centralizes month-end tasks; FloQast AutoRec, an AI-driven solution for automating reconciliations; and FloQast Flux, which alerts teams to actual variances by account. The software integrates seamlessly with popular accounting systems like QuickBooks, NetSuite, and SAP, allowing users to operate within familiar environments while minimizing manual errors. FloQast's innovative solutions are designed to improve accuracy in financial reporting and support compliance needs across various roles, including controllers and CFOs. Founded in 2013 and based in Los Angeles, California, the company also has a location in Dublin, Ohio, and maintains strategic alliances to further enhance its service offerings.

OM1, Inc. is a digital health company based in Boston, Massachusetts, that specializes in developing a platform aimed at measuring and forecasting patient outcomes data for healthcare organizations. The platform enables hospitals and health systems to fulfill requirements related to patient-reported and clinical outcomes, particularly within value-based care programs and bundle payments. By integrating predictive and prescriptive analytics, OM1's technology helps mitigate risks, lower costs, and enhance the understanding of healthcare outcomes across the care continuum. The company synthesizes and enriches clinical data to provide actionable insights that improve clinical, financial, and operational management, thereby establishing a new standard for health outcomes information. Founded in 2014, OM1 leverages a team of scientists, clinical experts, and software engineers to address the complexities of healthcare results.

Muna Therapeutics is a private biopharmaceutical company focused on discovering and developing therapies aimed at slowing or halting the progression of neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis. The company is dedicated to identifying innovative medicines that preserve cognitive functions and enhance resilience in individuals affected by these conditions. By prioritizing the development of suitable therapeutics, Muna Therapeutics aims to improve recovery outcomes for patients suffering from neurodegenerative diseases.

Wellthy, Inc. is a family care concierge service based in New York, established in 2014. The company specializes in assisting individuals and families managing complex care situations, particularly those involving chronic illnesses, aging-related issues, or disabilities. Wellthy connects families with dedicated Care Coordinators who help navigate the logistical and administrative challenges of caregiving. This includes organizing appointments, managing contacts, and storing essential documents. The service is designed to support families dealing with a range of health conditions, such as dementia, diabetes, heart disease, and cancer, as well as those requiring assistance with childcare and special needs. Through its platform, Wellthy aims to alleviate the burden of care management, allowing families to focus on their loved ones’ well-being.

CubicPV is a solar manufacturing company that focuses on producing wafers and tandem modules using advanced silicon and perovskite technologies. The company develops innovative semiconductor combinations for tandem modules, which enhance energy harvesting by utilizing two different light absorbers, thus improving efficiency across a broader spectrum of sunlight. This technology aims to reduce the cost of solar electricity to be competitive with conventional energy sources, such as coal. By manufacturing silicon wafers directly from the silicon melt, CubicPV streamlines the production process, eliminating several steps and effectively doubling the yield. This approach not only lowers the cost of clean electricity but also minimizes the carbon footprint associated with solar panel production, supporting the growing global demand for sustainable energy solutions.

Lyndra Therapeutics, Inc. is a biotechnology company that specializes in the development of ultra-long-acting oral medicines. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra focuses on creating orally administered dosage forms that provide sustained drug release for extended periods, ranging from a week to a month, while temporarily residing in the stomach. The company aims to address various therapeutic areas, including Alzheimer's, cardiovascular and metabolic diseases, psychiatric disorders, opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. By developing these innovative therapies, Lyndra seeks to enhance medication adherence, improve health outcomes, and ultimately reduce healthcare costs.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Kojin Therapeutics, founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, focuses on advancing a drug discovery platform that links complex cell states to established biochemical processes, specifically ferroptosis, which involves iron-dependent cell death. This innovative approach enables the development of targeted therapies for a wide range of challenging diseases that are often difficult to treat. The company's biology platform aims to identify disease-specific targets, ensuring that patients receive effective treatments tailored to their specific conditions. Kojin Therapeutics is supported by a diverse group of investors, including Polaris Partners, Newpath Partners, and AbbVie, among others.

Faro Health is a developer of a cloud-based medical platform that aims to standardize, automate, and streamline the challenges associated with clinical trials. The company's innovative platform utilizes an integrated clinical development environment, which simplifies the design and authoring processes of complex clinical studies. By leveraging advanced digital protocols, Faro Health provides clinical researchers with in-context, intuitive insights throughout the authoring process. This approach allows researchers to optimize their study designs by reducing the administrative burden of clinical protocols, enabling them to concentrate on the critical decisions that enhance clinical value.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering, developing, and commercializing treatments for serious and orphan diseases. The company leverages soluble guanylate cyclase (sGC) pharmacology to create next-generation sGC stimulators. Its pipeline includes Olinciguat, an orally administered vascular sGC stimulator in Phase II studies for sickle cell disease; Praliciguat, another oral sGC stimulator in Phase II trials for diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, a CNS-penetrant sGC stimulator in Phase I trials for neurodegenerative diseases. Additionally, Cyclerion is exploring liver-targeted and lung-targeted sGC stimulators. The company was incorporated in 2018.

Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

August Bioservices, LLC is a contract development and manufacturing organization (CDMO) based in Nashville, Tennessee, with an additional office in Celina, Tennessee. Established in 2017, the company specializes in offering a wide range of services for drug discovery, pharmaceutical development, and clinical manufacturing. Its research services encompass target validation, functional characterization, assay development, drug discovery, protein engineering, and both in vitro and in vivo testing. In the pharmaceutical development arena, August Bioservices provides formulation, process design, optimization, scale-up, and analytical method development. The company's clinical manufacturing capabilities include clinical trial supply, cGMP non-sterile and bulk manufacturing, aseptic fill and finish, and quality control. Additionally, it offers various testing services, such as pregnancy testing and viral disease testing, to clients in the pharmaceutical and biotechnology sectors. August Bioservices was previously known as PMI BioPharma Solutions until its name change in July 2020.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital medicine solutions. The company's core business involves creating video game-based technology to assess and enhance cognitive abilities. Akili's broad pipeline focuses on treating cognitive deficiencies and improving symptoms associated with various medical conditions, such as ADHD, MDD, ASD, and inflammatory diseases.

Engine Biosciences, established in 2014 and headquartered in Singapore, specializes in drug discovery and cellular reprogramming. The company's core offering is a validated platform that combines artificial intelligence and genetic perturbation to uncover gene interactions and biological networks. This platform enables researchers and drug developers to create targeted therapies and apply precision medicine. Engine Biosciences caters to prominent American corporations and research institutions, accelerating and reducing the costs of R&D for new medical therapies.

PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Hummingbird Bioscience is a biotechnology company specializing in the development of novel therapeutic antibodies for oncology and immuno-oncology indications. Utilizing systems biology approaches and proprietary computational platforms, they discover and engineer innovative biotherapeutics targeting challenging disease pathways with strong biological validation. Their pipeline includes lead assets HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA), both in cancer treatment. The company has formed strategic partnerships with Cancer Research UK and Amgen, and received a product development grant from the Cancer Prevention and Research Institute of Texas.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing adeno-associated virus (AAV) vectors for gene therapy applications. Its innovative platform utilizes artificial intelligence, next-generation DNA synthesis, and high-throughput sequencing to design and optimize AAV capsids, which are crucial for delivering therapeutic genes effectively and safely. By leveraging machine learning and quantitative experimentation, Dyno Therapeutics aims to revolutionize the design of gene vectors, focusing on enhancing cell-targeting capabilities. The company's approach seeks to advance the field of gene therapy, making it possible for researchers to access novel AAV vectors that can facilitate more efficient in vivo delivery of new treatments.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Cohere Health, Inc. is a healthcare technology company based in Boston, Massachusetts, founded in 2019. The company specializes in developing a platform that enhances collaboration among healthcare stakeholders, including patients, providers, and payers. Cohere Health focuses on improving the efficiency and effectiveness of healthcare delivery by simplifying complex processes through technology. Its primary offering is an intelligent prior authorization solution that is configurable to meet the specific needs of different health plans. This solution can be implemented as a fully outsourced utilization management service, utilizing artificial intelligence, machine learning, and real-time analytics to automate the prior authorization process. By doing so, Cohere Health aims to facilitate seamless communication and guide quality care throughout the patient journey, ultimately improving patient outcomes.

Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Tausight, Inc. is a software company founded in 2018 and headquartered in Sudbury, Massachusetts, with an additional office in San Francisco, California. The company focuses on mitigating healthcare cyber incidents related to patient data theft, addressing a critical need for chief information officers and chief information security officers in the healthcare sector. Tausight's software employs machine learning techniques to enhance the confidentiality, integrity, and availability of patient health information (PHI). By implementing a proactive risk management approach, the software aims to improve patient care, clinician satisfaction, regulatory compliance, and foster innovation within healthcare organizations.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Armorblox, Inc. is a cybersecurity company founded in 2017 and based in Cupertino, California. It specializes in developing data security solutions that focus on protecting the human layer within organizations. Utilizing advanced machine learning and artificial intelligence techniques, Armorblox addresses identity-based attacks and data loss, providing comprehensive security for its clients. The company's innovative approach aims to enhance overall data protection and safeguard sensitive information in an increasingly complex digital landscape.

Livara Health is a provider of non-operative, personalized treatment for musculoskeletal conditions, focusing specifically on back and neck problems. The company has developed an orthopedic care management platform that offers a data-driven, non-invasive back pain program. This program assesses patients' needs and customizes a comprehensive six-week treatment plan aimed at delivering relief. Patients receive physical therapy coaching, which can be accessed both online and onsite, to support their progress throughout the program. Livara Health's approach allows individuals to manage their musculoskeletal issues effectively without the need for surgical intervention.

Folx Health is a telehealth platform established in 2020, based in Boston, Massachusetts, that specializes in providing digital healthcare services for the LGBTQIA+ community. The company focuses on creating a medical service marketplace tailored to the needs of queer and trans individuals, offering access to a network of specialized clinicians. Folx Health's services include gender-affirming hormone therapy, sexual health care, fertility testing, and general medical services. The platform emphasizes discreet delivery of at-home kits for medications, labs, and supplies, enabling users to manage their health without the barriers and stigma often found in traditional healthcare settings.